Allele-specific differences in apolipoprotein C-III mRNA expression in human liver

Clinical Chemistry

Volumn 45, Issue 3, 1999, Pages 331-339

  Esterbauer, Harald ^a   Hell, Emanuel ^b   Krempler, Franz ^b   Patsch, Wolfgang ^a  

^a Salzburger Landeskliniken   (Austria)

^b Krankenhaus Hallein   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; MESSENGER RNA;

ALLELE; ARTICLE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; LABORATORY; LIPOPROTEIN SYNTHESIS; NUCLEOTIDE SEQUENCE; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS;

EID: 0032962692     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.3.331     Document Type: Article

References (41)

1. 1. Breslow JL. Familial disorders of high density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. New York: McGraw-Hill, 1995:1251-66.
2. 2. Bruns GA, Karathanasis SK, Breslow JL. Human apolipoprotein A-I-C-III gene complex is located on chromosome 11. Arteriosclerosis 1984;4:97-102.
3. 3. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 1993;100:157-69.
4. 4. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220-5.
5. 5. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Investig 1985;75:384-90.
6. 6. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein. J Clin Investig 1997;99: 2672-81.
7. 7. Aalto-Setala K, Weinstock PH, Bisgaier CL, Wu L, Smith JD, Breslow JL. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res 1996;37:1802-11.
8. 8. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Investig 1992;90:1889-900.
9. 9. Karathanasis SK, Ferris E, Haddad IA. DNA inversion within the apolipoproteins AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis. Proc Natl Acad Sci U S A 1987;84:7198-202.
10. 10. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990;249:790-3.
11. 11. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994;269:23610-6.
12. 12. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville, J, Anwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Investig 1995;95:705-12.
13. 13. Surguchov AP, Page GP, Smith L, Patsch W, Boerwinkle E. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1996;16: 941-7.
14. 14. Dallinga-Thie GM, Bu XD, van Linde-Sibenius Trip M, Rotter JI, Lusis AJ, de Bruin TW. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 1996;37:136-47.
15. 15. Dallinga-Thie GM, van Linde-Sibenius Trip M, Rotter JI, Cantor RM, Bu X, Lusis AJ, de Bruin TW. Complex genetic contribution of the Apo AI-CIII/-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. J Clin Investig 1997;99:953-61.
16. 16. Shoulders CC, Grantham TT, North JD, Gaspardone A, Tomai F, de Fazio A, et al. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. Hum Genet 1996;98:557-66.
17. 17. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci U S A 1993;90:4562-6.
18. 18. Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol 1997;17:2753-8.
19. 19. Talmud PJ, Humphries SE. Apolipoprotein C-III gene variation and dyslipidaemia. Curr Opin Lipidol 1997;8:154-8.
20. 20. Hong SH, Park WH, Lee CC, Song JH, Kim JQ. Association between genetic variations of apo AI-CIII-AIV cluster gene and hypertriglyceridemic subjects. Clin Chem 1997;43:13-7.
21. 21. Rees A, Stocks J, Sharpe CR, Vella MA, Shoulders CC, Katz J, et al. Deoxyribonucleic acid polymorphism in the apolipoprotein A-1-C-III gene cluster. Association with hypertriglyceridemia. J Clin Investig 1985;76:1090-5.
22. 22. Shoulders CC, Harry PJ, Lagrost L, White SE, Shah NF, North JD, et al. Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. Atherosclerosis 1991;87: 239-47.
23. 23. Shoulders CC, Ball MJ, Baralle FE. Variation in the apo AI/CIII/AIV gene complex: its association with hyperlipidemia. Atherosclerosis 1989;80:111-8.
24. 24. Ordovas JM, Civeira F, Genest J Jr, Craig S, Robbins AH, Meade T, et al. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis 1991;87:75-86.
25. 25. Rees A, Stocks J, Paul H, Ohuchi Y, Galton D. Haplotypes identified by DNA polymorphisms at the apolipoprotein A-1 and C-III loci and hypertriglyceridaemia. A study in a Japanese population. Hum Genet 1986;72:168-71.
26. 26. Rees A, Stocks J, Williams LG, Caplin JL, Lowett NI, Camm AJ, Galton DJ. DNA polymorphisms in the apolipoprotein C-III and insulin genes and atherosclerosis. Atherosclerosis 1985;58:269-75.
27. 27. De Lorenzo F, Rubba P, Monticelli A, Cocozza S. Coronary heart disease, echo-Doppler evidence of peripheral arterial disease and polymorphism of apolipoprotein B gene and Apo AI/CIII cluster. Angiology 1993;44:785-90.
28. 28. Ferrell RE, Kamboh MI, Majumder PP, Valdez R, Weiss KM. Genetic studies of human apolipoproteins. XIII. Quantitative polymorphism of apolipoprotein C-III in the Mayans of the Yucatan Peninsula. Hum Hered 1990;40:127-35.
29. 29. Patsch W, Sharrett AR, Chen IY, Lin-Lee YC, Brown SA, Gotto AM Jr, Boerwinkle E. Associations of allelic differences at the A-I/C-III/A-IV gene cluster with carotid artery intima-media thickness and plasma lipid transport in hypercholesterolemic-hypertriglyceridemic humans. Arterioscler Thromb 1994;14:874-83.
30. 30. Karanthanasis SK, Zannis VI, Breslow JL. Isolation and characterization of cDNA clones corresponding to two different human apoC-III alleles. J Lipid Res 1985;26:451-6.
31. 31. Tsai MY, Hanson NQ, Copeland KR, Beheshti I, Garg U. Determination of a T/G polymorphism at nucleotide 3206 of the apolipoprotein C III gene by amplification refractory mutation system. Clin Chem 1994;40:2235-9.
32. 32. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Investig 1995;96:2601-5.
33. 33. O'Brien RM, Lucas PC, Forest CD, Magnuson MA, Granner DK. Identification of a sequence in the PEPCK gene that mediates a negative effect of insulin on transcription. Science 1990;249: 533-7.
34. 34. O'Brien RM, Bonovich MT, Forest CD, Granner DK. Signal transduction convergence: phorbol esters and insulin inhibit phosphoenolpyruvate carboxykinase gene transcription through the same 10-base-pair sequence. Proc Natl Acad Sci U S A 1991;88: 6580-4.
35. 35. Hixson JE, Vernier DT, Powers PK. Detection of Sstl restriction site polymorphism in human APOC3 by the polymerase chain reaction. Nucleic Acids Res 1991;19:196.
36. 36. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
37. 37. Esterbauer H, Oberkofler H, Liu YM, Breban D, Hell E, Krempler F, Patsch W. Uncoupling protein-1 mRNA expression in obese human subjects: the role of sequence variations at the uncoupling protein-1 gene locus. J Lipid Res 1998;39:834-44.
38. 38. Frohman MA, Dush MK, Martin GR. Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. Proc Natl Acad Sci U S A 1988; 85:8998-9002.
39. 39. Zuker M, Jaeger JA, Turner DH. A comparison of optimal and suboptimal RNA secondary structures predicted by free energy minimization with structures determined by phylogenetic comparison. Nucleic Acids Res 1991;19:2707-14.
40. 40. Sachs AB. Messenger RNA degradation in eukaryotes. Cell 1993; 74:413-21.
41. 41. Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 1993;72:19-28.